Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous product, as reported by Johnson & Johnson (JNJ) were $2.499B in the third quarter of 2023. Net trade sales were $1.369B in the U.S. and $1.130B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
- Genmab price target raised to $46 from $44 at BTIG
- Genmab downgraded to Hold from Buy at Nordea
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab announces EC approval of TEPKINLY for adults with R/R DLBCL